BuEAM Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat Diffuse Large B Cell Lymphoma (DLCBL)
Status:
Unknown status
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and toxicity of busulfan, etoposide,
cytarabine and melphalan (BuEAM) including intravenous busulfan instead of BCNU of standard
BEAM as a conditioning for autologous stem cell transplantation in patients with NHL.